ER+/HER2− cancer cells, instead, sense the microenvironment activating inflammatory and metabolic pathways, and the resulting transcriptional changes, when detected in clinical tumors, are associated with a grim prognosis for women with ESRI+/ERBB2− tumors. Here, ERBB2 is linked to cancer.